Clinical Trials Logo

Thrombocytopenia clinical trials

View clinical trials related to Thrombocytopenia.

Filter by:

NCT ID: NCT05929248 Not yet recruiting - Clinical trials for Systemic Lupus Erythematosus

Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia

Start date: July 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of telitacicept in patients with systemic lupus erythematosus and refractory thrombocytopenia

NCT ID: NCT05864014 Not yet recruiting - Clinical trials for Chemotherapy-Induced Thrombocytopenia

Hetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.

Start date: May 2023
Phase: Phase 3
Study type: Interventional

The purpose of current study is to evaluate the efficacy and safety of hetrombopag for the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumors.

NCT ID: NCT05694130 Not yet recruiting - Clinical trials for Sjogren Syndrome With Other Organ Involvement

Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SS

Start date: February 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus combined with Glucocorticoid for Sjogren's syndrome patients with severe thrombocytopenia.

NCT ID: NCT05692128 Not yet recruiting - Neonatal Sepsis Clinical Trials

Frequency and Severity of Thrombocytopenia in Neonatal Sepsis

Start date: September 2023
Phase:
Study type: Observational

The aim of our study was to find the frequency of thrombocytopenia and its severity in neonates with sepsis

NCT ID: NCT05685420 Not yet recruiting - Clinical trials for Immune Thrombocytopenia

Extension Study of Herombopag for Pediatric Patients With Chronic Immune Thrombocytopenia

Start date: January 23, 2023
Phase: Phase 3
Study type: Interventional

The main purpose of this extended study is to enable subjects who are currently receiving the PartB experimental drug in the HR-TPO-ITP-III-PED clinical trial .To continue receiving the experimental drug after the completion of the clinical trial if they benefit from the treatment at the end of the clinical trial.Until the study physician determines that the subject has failed treatment or that the subject can no longer benefit from treatment or extends the study treatment for 6 months.In addition, the secondary purpose of this extended study was to observe the long-term efficacy and safety of tripodal in children and adolescents.

NCT ID: NCT05678335 Not yet recruiting - Clinical trials for Sjogren Syndrome With Other Organ Involvement

Tacrolimus for Thrombocytopenia in SS

Start date: February 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus for Sjogren's syndrome patients with thrombocytopenia.

NCT ID: NCT05672420 Not yet recruiting - Anemia Clinical Trials

Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies

Start date: January 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the study is to explore the safety and efficacy of umbilical cord derived mesenchymal stem cells in treatment-induced myelosuppression in patients with hematologic malignancies.

NCT ID: NCT05654766 Not yet recruiting - Acute Leukemia Clinical Trials

Assesment of the Functional Activity of Platelets for the Differential Diagnosis of Thrombocytopathies

Start date: January 2, 2023
Phase:
Study type: Observational

The purpose of this study is to develop a highly sensitive method for assessing the functional activity of platelets for use in the differential diagnosis of thrombocytopenia and platelet defects.

NCT ID: NCT05634824 Not yet recruiting - Pregnancy Related Clinical Trials

IVIg Plus Low Dose rhTPO for ITP in Pregnancy

Start date: January 1, 2023
Phase: Phase 2
Study type: Interventional

Randomized, open-label, multicenter study to investigate the efficacy and safety of IVIg plus low-dose recombinant thrombopoietin in pregnant patients with corticosteroid or IVIg monotherapy-resistant ITP.

NCT ID: NCT05613296 Not yet recruiting - Clinical trials for ITP - Immune Thrombocytopenia

Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP

Start date: February 2023
Phase:
Study type: Observational

This is a retrospective and prospective multicenter observational study with the aim to evaluate the real-life use of Fostamatinib in adult patients with chronic ITP, refractory to other treatments.